Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clesrovimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Clesrovimab - Merck Sharp & Dohme

Alternative Names: Anti RSV F antibody - Merck Sharp & Dohme; clesrovimab-cfor - Merck Sharp & Dohme; Enflonsia; MK-1654

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Respiratory syncytial virus infections

Most Recent Events

  • 09 Jun 2025 Merck Sharp & Dohme anticipates launch clesrovimab for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in USA (IM) in July 2025
  • 09 Jun 2025 The US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices expects to discuss and make recommendations for the use of clesrovimab for Respiratory syncytial virus infections (In infants, Prevention) in USA (IM), in June 2025
  • 09 Jun 2025 Adverse events data from the phase II/III CLEVER trial in Respiratory syncytial virus infections released by Merck Sharp & Dohme

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top